secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001935979-23-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven Q4 2022 net loss $201.1M; licenses TYK2/JAK1 inhibitor BHV-8000
------------------------------------------------------------------------

- Q4 2022 net loss $201.1M ($3.32/share); cash $465.3M at year-end, no debt.
- Acquired exclusive global ex-China rights to oral brain-penetrant TYK2/JAK1 inhibitor BHV-8000; Phase 1 start planned in 2023.
- Completed Phase 1 SAD/MAD for Kv7 activator BHV-7000; no sedation/dizziness/ataxia; plans EEG study H1 2023 and pivotal H2 2023.
- Appointed Bruce Car (CSO), Irfan Qureshi (CMO), Tanya Fischer (CDO) to management team.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597923000014/0001935979-23-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597923000014/bhvn-20230323.htm
  HTML page:      https://secwatch.observer/filing/0001935979-23-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer